Compare Natera Inc. Common Stock (NTRA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs VICI Properties Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while VICI Properties Inc trades at $23.2 (market cap $25.26B). The key difference: Natera Inc. Common Stock is far larger — about 2.3× VICI Properties Inc's market cap, and VICI Properties Inc pays a 8.02% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and VICI Properties Inc for 44 Days on average.
| NTRA | VICI | |
|---|---|---|
Market Cap | $57.03B | $25.26B |
Volume | 1,131,157 | 7,855,800 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $31.42 |
52-Week Low | $179.42 | $22.53 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $56.18B | $42.81B |
Dividend Yield | — | 8.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VICI Properties trades at $22.91, down 0.52% on the day, with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and 9.84% ROE. The stock shows mixed earnings performance with one beat and two misses in recent quarters, while analyst consensus remains strongly bullish with a $28.90 price target representing 26% upside. Recent corporate actions include a $0.46 dividend payment scheduled for October 2026.
The investment case balances attractive valuation metrics (P/E of 8.88, P/B of 0.86) against technical weakness and tenant concentration risks. While cash flow generation remains robust with $2.51B from operations in 2025, investors face headwinds from rising interest rates and potential tenant stress. The 75% buy rating from analysts suggests significant upside potential if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
